Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaxelis + meningococcal C conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Vaxelis is a hexavalent vaccine (DTaP-IPV-Hib-HepB) developed by MCM Vaccines B.V., a joint venture between Merck and Sanofi. This specific entry refers to the co-administration or combination of Vaxelis with a meningococcal serogroup C (MenC) conjugate vaccine. Vaxelis contains diphtheria and tetanus toxoids, acellular pertussis antigens (pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3), inactivated poliovirus (types 1, 2, and 3), Haemophilus influenzae type b conjugate (using a meningococcal protein carrier), and recombinant hepatitis B surface antigen. The addition of a MenC conjugate vaccine (such as MCC-TT or MCC-CRM) provides protection against Neisseria meningitidis serogroup C. This combination regimen is used for active immunization in infants and toddlers to prevent seven major infectious diseases.
- Brand names
- Vaxelis
- Other names
- DTaP-IPV-Hib-HepB + MenC
02
Targets
OmpC (Outer membrane porin C)HBsAg (Hepatitis B surface antigen)PRNP (Cellular Prion Protein)Neisseria meningitidis group C capsular polysaccharideDiphtheria toxinTT (Tetanus toxoid)
Beyond the preview
Go deeper on Vaxelis + meningococcal C conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxelis + meningococcal C conjugate vaccine.